TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)
NCT ID: NCT01242696
Last Updated: 2017-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1014 participants
OBSERVATIONAL
2010-11-30
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study
NCT01148329
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization
NCT01342822
A Prospective Evaluation in a Randomized Trial of TAXUS in the Treatment of De Novo Coronary Artey Lesions
NCT00693979
TAXUS PERSEUS Small Vessel
NCT00489541
Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ Stent
NCT01285999
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coronary artery stenting
All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
Coronary artery stenting
Coronary artery stenting with drug eluting stents
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coronary artery stenting
Coronary artery stenting with drug eluting stents
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharmaceutical Research Associates
OTHER
Boston Scientific Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Corrado Tamburino, Prof.
Role: PRINCIPAL_INVESTIGATOR
Ospedale Ferrarotto, Via Citelli, 1, 95100 Catania, Italy
Peter Maurer, PhD
Role: STUDY_DIRECTOR
Boston Scientific Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Algemeen Ziekenhuis Sint-Jan
Bruges, , Belgium
CHU de Charleroi - ISPPC
Charleroi, , Belgium
H-Hartziekenhuis Roeselare-Menen vzw
Roeselare, , Belgium
CH Avignon
Avignon, , France
CHU Besancon
Besançon, , France
Centre Hospitalier Privé Saint Martin gds
Caen, , France
CHU Grenoble
Grenoble, , France
Hôpital Privé Clairval
Marseille, , France
CHG de Pau
Pau, , France
Clinique Saint-Hilaire Rouen
Rouen, , France
Centre Hôpital Universitaire Rangueuil
Toulouse, , France
Kardiocentrum Frankfurt
Frankfurt am Main, Hesse, Germany
Krankenhaus d. Barmherzigen Brüder
Trier, Rhineland-Palatinate, Germany
Klinikum Coburg gGmbH
Coburg, , Germany
Zentrum für klinische Prüfungen in der Facharztzentrum Dresden-Neustadt GbR
Dresden, , Germany
Augusta Krankenhaus
Düsseldorf, , Germany
Krankenhaus Landshut-Achdorf
Landshut, , Germany
Medical School of University PECS
Pécs, , Hungary
Galway University Hospital
Galway, , Ireland
Ospedale Ferrarotto
Catania, , Italy
Ospedale Cannizzaro
Catania, , Italy
Ospedale Misericordia ASL 9
Grosseto, , Italy
Azienda Ospedaliera Papardo
Messina, , Italy
P. Stradins University Hospital
Riga, , Latvia
Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. Jana Pawla II
Grodzisk Mazowiecki, , Poland
Hospital General de Albacete
Albacete, , Spain
Hospital Universitario de Bellvitge
Barcelona, , Spain
Hospital General De Leon
León, , Spain
Hospital La Paz
Madrid, , Spain
H. Marques De Valdecilla
Santander, , Spain
Craigavon Hospital, Southern Trust
Craigavon, Northern Ireland, United Kingdom
Royal Bournemouth General Hospital
Bournemouth, , United Kingdom
Lister
Hertfordshire, , United Kingdom
London Chest Hospital
London, , United Kingdom
Freeman Hospital
Newcastle upon Tyne, , United Kingdom
Norfolk and Norwich University Hospital NHS Trust
Norwich, , United Kingdom
New Cross Hospital
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tamburino C, Capodanno D, Erglis A, Menown IB, Horvath IG, Moreno R, Gilbert TJ, Crowley JJ, Calabria P, Allocco DJ, Dawkins KD. One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE). EuroIntervention. 2015 Mar;10(11):1261-6. doi: 10.4244/EIJY15M01_01.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S2059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.